Evidence mapPaperPMID 32533989Full record

ReviewDiabetes research and clinical practice2020

Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: A narrative review.

Awadhesh Kumar Singh, Kamlesh Khunti

Open access · bronzeAbstract readReview
In one paragraph

Review in Diabetes research and clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 4 pooled it
2.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 4 syntheses or guidelines pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Effects of Metformin on COVID-19 Patients with Type 2 Diabetes: A Retrospective Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Awadhesh Kumar SinghDepartment of Diabetes & Endocrinology, G.D Hospital & Diabetes Institute, Kolkata, India. Electronic address: drawadheshkumarsingh@gmail.com.
Kamlesh KhuntiLeicester Diabetes Research Centre, Leicester LE5 4PW, UK. Electronic address: kk22@le.ac.uk.
GD Hospital & Diabetes Institute · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsRising prevalence of non-communicable diseases world-wide has made diabetes an important comorbidity in patients with coronavirus disease-19 (COVID-19). We sought to review the risk, severity and mortality in COVID-19 and its relation to the glycemic control, and role of anti-diabetic agents in patients with diabetes.

methodsA Boolean search was made in PubMed, MedRxiv and Google Scholar database until May 10, 2020 and full articles with supplementary appendix were retrieved using the specific key words related to the topic.

resultsThere is a high prevalence of diabetes in patients with COVID-19. Patients with diabetes had a significantly more severe variety of COVID-19 and increased mortality, compared to the groups without diabetes. Moreover, poor glycemic control is associated with a significantly higher severe COVID-19 and increased mortality, compared to the well-controlled glycemic groups. No data currently available for or against any anti-diabetic agents in COVID-19.

conclusionsDiabetes, in particular poorly-controlled group is associated with a significantly higher risk of severe COVID-19 and mortality. This calls for an optimal glycemic control and an increased emphasis on future preventative therapies including the vaccination programs for these groups in addition to the traditional risk prevention such as social distancing and self-isolation.

Indexed as

BetacoronavirusBlood GlucoseComorbidityCoronavirus InfectionsCOVID-19Diabetes ComplicationsDiabetes MellitusHumansHyperglycemiaHypoglycemic AgentsPandemicsPneumonia, ViralRisk AssessmentRisk FactorsSARS-CoV-2Blood GlucoseHypoglycemic AgentsAnti-diabetic agentsCOVID-19DiabetesMortalityRiskSARS-CoV-2Severity

Identifiers

PMID32533989
PMCPMC7286824
OpenAlexW3034800679

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.